Year | Outstanding achievements | PI |
2010 | Center of Excellence for Antibody Research (CEAR) was established with the 60 million baths supported from JICA. | Dr. Pongrama Ramasoota |
2013 | The 1st Neutralizing human monoclonal antibody (NhuMAb) neutralized all 4 serotypes of dengue virus was developed, and tested in challenged monkey. Two patents was issued in 11 countries. | Dr. Pongrama Ramasoota |
2015-2017 | NhuMAb against dengue virus without causing ADE was developed. (Fc modified NhuMAb) | Dr. Pannamthip Pitaksajjakul |
2019 | Licensing contract between BSV Bio-Sciences company and Mahidol University was signed. GMP Production of NhuMAb was done and clinical trials will be performed in 2022-2025. | Dr. Pongrama Ramasoota |
Patents
- Antigenic Peptide Derived From Dengue Virus
- Dengue Virus Serotype Neutralizing Antibodies Patent issue for 9 countries (Australia, India, Indonesia, Lao, Philippine, Singapore, Thailand, U.S.A and Vietnam)
- Us-patent number 3190-170; Efficient preparation of Human Monoclonal antibody To Neutralize All Serotypes of Dengue Virus Using Peripheral Blood Lymphocytes From Patients.
- Us-patent number 3190-181; Epitope-Based Vaccine With Dengue Virus Domain II Immunogens Derived From The Recognition Region By Dengue Patients’ Peripheral Blood Lymphocyte-Derived Human Monoclonal Antibodies Showing Neutralization of All Four Serotypes Of Dengue Virus
- Dengue-virus serotype neutralizing antibodies but suppress induction of infection-enhancing antibody Japanese Patent Application PCT/JP2017/015384
- สิทธิบัตร เรื่อง โมโนโคลนอลแอนติบอดีสำหรับวินิจฉัยโรคปากเท้าเปื่อยและวิธีการผลิตโมโนโคลนอลแอนติบอดี (กำลังยื่นขอสิทธิบัตรในประเทศไทย) เลขที่คำขอ 1601003461)